[INV4]

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

July 16, 2025

Klotho Neurosciences Maintains Listing on the NASDAQ

NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).

The Company is now in full compliance with all NASDAQ continued listing requirements and will remain listed and traded on the NASDAQ Stock Market.

NASDAQ will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement for a period of one year. Should the Company fall out of compliance with the minimum equity rule during that time, the Company would become subject to delisting without a cure period but will have the opportunity to request a new hearing should that event occur.

About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, please visit the company's website at www.klothoneuro.com.

Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFO
[e-mail]

https://ih.advfn.com/stock-market/NASDAQ/klotho-neurosciences-KLTO/stock-news/96439777/klotho-neurosciences-inc-regains-full-compliance

$KLTO

[weedtrader420]

I got all my money back plus a little profit i’m out 🥳 good luck

[bcapps66]

And we're RED...

[INV4]

This is one to keep an eye on! Not going anywhere will only add if it dips.
Holding long term 💹

GLTA $KLTO

[weedtrader420]

🧹🥳🚀🧹🥳🚀🧹🥳 🚀

[weedtrader420]

🧹🫲😎

[INV4]

On July 10, 2025, Klotho Neurosciences experienced a significant surge in its stock price, rising by 45.99% in pre-market trading. This substantial increase can be attributed to several key developments that have bolstered investor confidence in the company's prospects.

One of the primary drivers behind this surge is the recent FDA Orphan Drug Designation granted to Klotho Neurosciences for its ALS treatment candidate, KLTO-202. This designation provides the company with significant regulatory advantages, including tax credits, user fee waivers, and market exclusivity for seven years, which can greatly enhance the development and commercialization of KLTO-202.

In addition to the regulatory benefits, Klotho Neurosciences has made significant progress in advancing KLTO-202 to the manufacturing phase. This development is crucial as it brings the company one step closer to initiating clinical trials, which are essential for demonstrating the safety and efficacy of the treatment. The company's proactive approach in preparing for these trials has been well-received by investors, contributing to the positive market sentiment.

Overall, the combination of regulatory support and strategic advancements in the development of KLTO-202 has positioned Klotho Neurosciences favorably in the market, leading to the notable increase in its stock price. As the company continues to make progress in its ALS treatment efforts, it is likely to attract further attention from investors and stakeholders in the healthcare sector.

https://www.ainvest.com/news/klotho-neurosciences-stock-soar-45-99-2507/

$KLTO 💹

[weedtrader420]

Yeah, I got a little beat up. That’s OK. I’ll hang in there.💪🤑

[bcapps66]

Oh well... done with this. This thing is a turd. I keep holding and hoping but always disappoints. Good luck!!

[weedtrader420]

😋😋😋

[bcapps66]

Think we need to be honest with ourselves.... it's not going to be the great day we are hoping for.... might even go red

[weedtrader420]

☝️🥳☝️🚀

[bcapps66]

I think 200% is a big wish. If it was up 100% already then maybe. Got the volume but not the pps

[weedtrader420]

I think some point of the day or morning they’ll get interested again☝️🥳☝️

[bcapps66]

This is true....let's see if they let it run

[glenn1919]

KLTO............................................https://stockcharts.com/h-sc/ui?s=KLTO&p=W&b=5&g=0&id=p86431144783

[weedtrader420]

You never know🫲🥳🫱,volume is picking up

[bcapps66]

That would be nice....BUT....not looking like that's going to happen.

[weedtrader420]

Looking for a 200% day here today

[weedtrader420]

☝️🥳☝️

[INV4]

Great start today 😃

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

https://ih.advfn.com/stock-market/NASDAQ/klotho-neurosciences-KLTO/stock-news/96405626/klotho-neurosciences-inc-granted-fda-orphan-drug

$KLTO 💹

[INV4]

At Small Cap Exclusive, it usually takes 3 strong catalysts to feature a company in a full research report — KLTO has 8. Here’s why it’s turning heads.

July 7, 2025

In biotech, few small-cap names demonstrate both scientific depth and financial discipline. Klotho Neurosciences (NASDAQ:?KLTO) has suddenly emerged as one of these exceptional companies. Backed by more than $11 million in new capital, now completely debt-free, and advancing the manufacturing phase of its lead ALS gene therapy program, KLTO is executing with rare clarity and purpose. For investors tracking gene therapy, longevity biology, and neurodegenerative research, this is not just another speculative biotech—it’s a Nasdaq-listed performer converting milestones into market momentum.

Here’s a deeper dive into what’s unfolding—and why KLTO merits a spot on your watchlist.

1. $11 Million Raised, All Debt Retired, Nasdaq Compliance Secured
In mid-June, KLTO announced a critical financial milestone: over $11 million raised via warrant exercises, with $3.1 million immediately used to retire all outstanding debt. Having no debt on its balance sheet is uncommon for micro- to small-cap biotech names, and this move restored KLTO into full compliance with Nasdaq’s equity requirements. The company’s fiscal discipline, combined with strong investor appetite, reflects confidence in management and the underlying science—an uncommon alignment at this stage.

2. Transition to Manufacturing—KLTO-202 ALS Gene Therapy
On June 30, 2025, KLTO revealed it had begun manufacturing and process development for KLTO-202, its investigational gene therapy targeting ALS.. This is more than just symbolic: the shift from discovery to production typically marks a major value inflection in biotech.

KLTO’s investigational therapy uses a secreted Klotho (s-KL) gene variant packaged in an adeno-associated virus (AAV) designed to deliver neuroprotective protein to motor neurons. Animal studies across Alzheimer’s, accelerated-aging, and ALS models have already demonstrated favorable results. With manufacturing underway, the company targets IND filing and Phase I/II trials by late 2026.

3. Proprietary s-KL Platform: Uniquely Positioned in Neurodegeneration
KLTO’s therapeutic focus is not generic—it’s built on a novel biological insight. Licensed from the Autonomous University of Barcelona, the s-KL gene variant is concentrated in neurons of the spinal cord and brain. Unlike the membrane-bound form of Klotho that regulates kidney function, this secreted variant minimizes both neuroinflammation and oxidative stress.

Preclinical results have been impressive: 20–40% lifespan extension and significant neuroprotective effects in mouse and non-human primate models.. Crucially, these findings are peer-reviewed and not anecdotal, providing real scientific foundations for further development.

4. Strategic Clarity After Terminating SkyBell Deal
Earlier this June, KLTO formally ended its planned share-exchange deal with SkyBell Technologies. While terminating a deal sounds mundane, here it signals clean focus and avoidance of unnecessary dilution. Gone is the risk of dispersing shareholder value or managerial bandwidth—the company is now fully dedicated to advancing therapeutic candidates that matter.

5. Market Recognition via Retail Momentum
KLTO’s share price erupted in June, soaring roughly 800% at one point on news of positive preclinical data. Trading volume exploded as retail investors entered the fray, giving the stock greater visibility. Technical patterns point to a classic breakout scenario, supported by momentum-driven platforms flagging KLTO as a trigger?. In small-cap biotech, rising sentiment among retail often precedes institutional interest—especially when backed by genuine pipeline progress.

6. Lean Execution via CRO Partnerships
Rather than hiring large teams, KLTO is leanly outsourcing its manufacturing and clinical work to contract research organizations (CROs). This is a cost-effective path that minimizes overhead while tapping specialized expertise—a capital-efficient approach at a stage when large burn rates can quickly dilute value.

7. Strong Leadership Anchored in Scientific and Financial Acumen
Led by Dr. Joseph Sinkule, founder and CEO, KLTO drives both scientific innovation and strategic oversight. Meanwhile, involvement of Chardan Capital Markets as financial advisor during the warrant exercise signals disciplined capital strategy and institutional alignment. Now, investors have both a tight scientific roadmap and prudent fiscal leadership.

8. Upcoming Catalysts Through 2026
With manufacturing underway now and projected to take roughly eight months, KLTO is positioning for a major milestone by Q3 2026:?submission of an IND and launch of Phase I/II clinical trials in ALS patients.. Each of these milestones—process development completion, FDA meetings, safety studies, trial site training, and first dosing—offers opportunity for renewed market attention and stock movement.

Why This Story Matters Now
• Differentiated biology: s-KL is distinct from other Klotho approaches; it’s specifically targeted for neuroprotection, not broad metabolic function.
• Capital discipline: Debt-free with fresh capital and minimal burn.
• Strategic execution: Manufacturing and regulatory runway right ahead, avoiding distractions.
• Retail momentum and institutional signaling: Volume and visibility combining with disciplined strategy.
• Clinical timeline is tangible: Trial milestones visible by late 2026 with clear steps in between.

For investors tracking neurodegeneration or high-impact gene therapy plays, KLTO offers a capital-efficient biotech story on Nasdaq—scalable, focused, and grounded in science.

https://smallcapexclusive.com/klotho-neurosciences-nasdaq-klto-11-million-raised-als-gene-therapy-manufacturing-underway-a-disruptor-on-the-nasdaq/

$KLTO 💹

[INV4]

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

July 10, 2025

NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS.

The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications. Additionally, Orphan Drug Designation of the product provides the developers seven years of US market exclusivity and independent from the Company's intellectual property protection.

"Receiving the Orphan Drug Designation for s-KL-AAV.myo for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule.

ALS is sometimes referred to as Lou Gehrig's disease. Lou Gehrig, who played for the New York Yankees for 17 years in the 1920s and 1930s, stunned players and fans by retiring from baseball at the age of 36 after being diagnosed with ALS. Prior to this diagnosis, Gehrig played in a record-breaking 2,130 consecutive games, was referred to as the "Iron Horse," and was considered one of the greatest baseball players of all time. Less than two years later, at the age of 37, Gehrig died of complications from ALS. ALS is also referred to as Motor Neuron Disease in the UK and elsewhere. ALS is considered a rare disease and affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year.

Klotho Neurosciences will have completed "proof of concept" studies in two animal models of human ALS and the Company is currently initiating manufacturing of the ALS-targeted product candidate, followed by meetings with the U.S. FDA and EMA in Europe to concur with the development path going forward.

KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority.

About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, please visit the company's website at www.klothoneuro.com.

Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFO
[e-mail]

https://ih.advfn.com/stock-market/NASDAQ/klotho-neurosciences-KLTO/stock-news/96405626/klotho-neurosciences-inc-granted-fda-orphan-drug

$KLTO 💹

[INV4]

Klotho advances ALS gene therapy KLTO-202 to manufacturing phase

July 8, 2025

https://alsnewstoday.com/news/als-gene-therapy-klto-202-advances-manufacturing-phase/

$KLTO 💹

[Eddo1976]

Maybe I missed something here, but was a dividend paid out in shares?  I've had three different purchases over the last few weeks.  Lots of 100 shares, 900, and 1000 for 2,000 total shares.  Yesterday my Schwab now shows 2,056 shares.  

[INV4]

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

June 30, 2025

NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS).

A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage.

The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead.

Dr. Joseph Sinkule, the Company's CEO and founder commented: "With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death."

ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis.

About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
[e-mail]

Website: www.klothoneuro.com

https://ih.advfn.com/stock-market/NASDAQ/klotho-neurosciences-KLTO/stock-news/96331459/klotho-neurosciences-moves-forward-with-manufactur

$KLTO

[RandolRocketman]

Not surprised by anything with KLTO. 20% longer life? Seriously, who wouldn't sign up, even if it's half that? Play this one like a fiddle, but always keep some and average down if you have to. I just would not want to be out of this when the news hits that it's going into next phase. Anyone else smell a buyout? Would that help or hurt?

[INV4]

Everything depends on the progress/timeline/approvals etc. But news about extending longevity and healthy longevity was/is great. A lot of people are waiting for something like this IMHO.

==================

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("a-KLOTHO")

June 09, 2025 - 7:00AM

Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho.

NEW YORK, June 9, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span.

Pioneering discoveries by Professor Makoto Kuro-O in 1997 showed that Klotho concentrations in the blood were directly associated with lifespan of mammals – the lower the Klotho blood levels the shorter the lifespan. Kuro-O's laboratory then published the first evidence that genetic over expression of the full-length form of Klotho in mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan. Since then, the Klotho protein has gained much attention because of its ability to influence key biological pathways involved in metabolism, inflammation and tissue repair, which are closely linked to the aging process.

A series of experiments led by Joan Roig-Soriano and colleagues, published in the February 2025 edition of Molecular Therapy, highlights the promising role of the naturally occurring secreted form of the Klotho protein ("s-KL") and its effects on healthy aging mice and mice with a rapidly aging phenotype. Key observations were that, while aging is a major risk factor for many pathologies, including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis, the secreted protein s-KL has emerged as a potentially promising therapeutic anti-aging molecule due to its many biological effects involving multiple pathways related to cell injury, stress, and inflammation. The s-KL was administered using an adeno-associated virus serotype 9 delivery vector (AAV9) that expressed the secreted KL protein isoform and efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan.

Dr. Joseph Sinkule, the CEO of Klotho Neurosciences (KLTO) commented that "KLTO has secured an exclusive worldwide license for s-Kl from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, we have the exclusive use of patents issued in the USA, Europe, and China covering a secreted splice variant of mammalian Klotho referred to as s-KL, as a treatment for neurodegenerative and age -related disorders. Professor Makoto Kuro-O is also a scientific advisor to KLTO. This recently published paper provides further credence to our development of s-KL as a treatment to reduce age-associated degeneration where, as a company, KLTO has a particular focus on neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span".

About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:
Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
[e-mail]

Website: www.klothoneuro.com.

https://ih.advfn.com/stock-market/NASDAQ/klotho-neurosciences-KLTO/stock-news/96205066/klotho-neuroscience-inc-announces-an-approach-to

$KLTO 💹

[glenn1919]

KLTO.......................................................p/m

[RAlbert]

My average is 1.57 will it come back again? Lost lot of $s on paper

[RAlbert]

No more dilution. Strengthening share price. Ready for spike… potential $10 stock

[glenn1919]

KLTO.................................................................https://stockcharts.com/h-sc/ui?s=KLTO&p=W&b=5&g=0&id=p86431144783

[ollik78]

Here we Go 🚀

[Acme Investments]

Don't assume something negative when it doesn't fit your goals!! First there are plenty of companies that do offerings over their share price!! Instead of doing some research you went on the attack!! Good luck!!

[RAlbert]

So you have the short position and trying to cover losses by spreading negative. Best of luck…

Now my target is $10 for this.

[Acme Investments]

That's false Sir!! It can and will go lower!!

[RAlbert]

Warrants are issued at $1.35 it cannot go lower than the warrant price. I feel we see $5 mark soon by next week, if not earlier.

[Acme Investments]

Suit yourself!! Some like to be a worker bee!! Cowardly lion or Tin man?? Lol 😂

[TrendTrade2016]

WHAT POSITIONS...LMAO...YOUR OTC BAGS ARE NOT POSITIONS

[Acme Investments]

Don't be So dumb!! I eat and check my positions before I waste time playing with You!! I gave you a jewel and this is the Thanks I get??

[TrendTrade2016]

OKAY...BROKE BOY...FAKE MILLIONAIRE...TROLLS IHUB FROM NOON TO 4PM...GO GET Y0UR BREAKFAST

[Acme Investments]

To each his own!! I lead not follow!! My way made me a million or almost 2!! You career loser!! You can't get a heavy position and take serious educated risk Day trading!! That's why you've never ascended!! Pussy!! Lol 😂

[makinezmoney]

$KLTO: Ranked #45 out of top 1250 iHubbers

Not a bad ranking .......... thanks to the fans like INV4......... I love to see you PROSPER & do WELL !

After all........... you deserve it and thanks for taking heed to getting in early.
When I see action, I report action.... plain and simple.


More goodies to COME still.

One of my best plays so far was those Oct $50 $CRWV calls............. WOW !

GO $KLTO

[makinezmoney]

$KLTO: Rock on Buddy........ $KLTO tapped $3.80

Now thats what we call a BANNNNGERRRRRRRRRRRRR !!!!!!!!!!!!!!!!

Net $3.10 GAINER !!!!!!!!!!!!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176293476


Wow.... whatta RIOT.

Got some more solid bangers coming for your just like I always do... you know me.


GO $KLTO

[INV4]

Still going up 🤑 Wow! Awesome 😁
HOD $3.90

$KLTO 💹

[INV4]

Enjoy your sub buddy 🤩
Have a great day.

$KLTO 💹

[makinezmoney]

$KLTO: Wow...... $3.30 !!!!!!!!!!!!!!!!!!

Parrtyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy


Wuz my name.




GO $KLTO

[makinezmoney]

$KLTO: Gave it to you at $0.70..... now $2.90 !!!!!!!!!!

How'm I doin so far, huhhhhhhhhhhhhhhhhhhhh

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176293476


Hook me up with an ihub sub peeps so i can keep it going........ you know you wanna make some EZ MONEY

Watch $CARM today........ starting off like $KLTO did yesterday

GO $KLTO

[INV4]

Great start this morning HOD $3.20. Still holding up nicely 💹, after a day of almost 1,000% 🤩

GLTA $KLTO 😃

[bambam56]

Looks like half a mil cash on hand ?